BPC-157

BPC-157 is a synthetic 15-amino-acid peptide studied for its effects on tissue injury and repair. Interest began with digestive protection and expanded to tendon, muscle, ligament and wound experiments. Several rat studies reported improvements in both the organization of damaged tissue and its performance, including tendon strength and walking. Cell experiments have since examined movement, survival, growth-signal responsiveness and vascular behavior that could contribute to these outcomes. The human literature is much smaller: it includes reports of knee-pain and bladder-symptom improvement, brief tolerability observations and older digestive studies summarized by FDA. The published knee and bladder reports have no comparison groups, leaving the contribution of BPC-157 to the reported relief uncertain.

Overview

The name BPC-157 comes from “body protection compound,” a term associated with early gastric-juice research. Published papers also use BPC-15 and PL 14736. The sequence is GEPPPGKPADDAGLV, with 15 amino-acid residues ordered from the N-terminus to the C-terminus. The molecular profile below identifies the free base using the FDA identity table and PubChem record.

Molecular profile

Type: Synthetic 15-amino-acid peptide
Sequence: GEPPPGKPADDAGLV
Molecular formula: C₆₂H₉₈N₁₆O₂₂
Molecular weight: 1419.5 g/mol
CAS number: 137525-51-0
UNII: 8ED8NXK95P
Chemical form: Free base

The molecular fields identify the 15-residue BPC-157 free base. Formula, mass and identifiers follow the form recorded in FDA’s identity table. Source: FDA briefing document (2026), Table 1.

Explore the amino-acid sequence

G: glycine; E: glutamate; P: proline; K: lysine; A: alanine; D: aspartate; L: leucine; V: valine.

Each letter identifies one amino-acid residue, ordered from the N-terminus to the C-terminus in this sequence map. PubChem: BPC-157, CID 9941957.

The acetate form pairs the peptide with acetate. FDA records a variable acetate composition and provides no single molecular weight for that form. Naming the form gives the formula and mass a clear chemical meaning and helps distinguish the preparations described in individual papers.

Uses and research areas

BPC-157 research spans surgically injured tendons, muscles and ligaments, chemically damaged intestinal lining, alkali-burn wounds and restricted limb circulation. Each model tests a particular component of injury or recovery. Mechanical testing asks how much load a repaired tissue can withstand; walking measurements show how an animal uses the injured limb; microscopy reveals the organization of the repair tissue.

For example, Staresinic and colleagues (2003) completely transected rats' Achilles tendons and compared BPC-157 with saline over 14 days. Treated rats had better-organized repair tissue and improved walking scores. Their tendons tolerated more force before failure and showed improved elastic properties.

The human reports address different clinical problems. Knee-treatment patients described their pain after local injections, while a bladder study recorded symptoms in women with interstitial cystitis. Their designs and outcomes are developed in Research findings, alongside the older ulcerative-colitis account.

Mechanism of action

Repair depends on the coordinated work of several cells and tissues. Fibroblasts build and maintain connective tissue, but they must also reach the damaged area, attach to their surroundings and survive the local conditions. Growth signals influence their activity, and vessels supply the oxygen and nutrients needed by the recovering tissue. BPC-157 experiments have examined these processes through separate tendon-cell and endothelial-cell models. Keeping that biological sequence in view makes the reported signaling changes easier to interpret.

Cell movement and tube assembly in BPC-157 experiments

Repair cells must reach damaged tissue and work within it. These schematics show attachment and movement in a tendon fibroblast and assembly by vessel-lining cells on a culture surface.

Tendon fibroblasts

Actin helps a fibroblast change shape. Focal-adhesion attachment points link its internal fibres to the surrounding matrix, with FAK and paxillin participating in signaling at those sites.

Reported observations: greater tendon outgrowth, cell migration, spreading and survival during hydrogen-peroxide stress, with increased FAK/paxillin phosphorylation. The proliferation assays were unchanged. Chang and colleagues (2011), Results and Figures 3–6.

Vessel-lining cells

Endothelial cells move and assemble into connected tube-like structures on a culture surface. A tube-formation assay records the extent of this arrangement.

Reported observations: greater movement and tube formation in culture. Separate rat experiments measured alkali-burn wound repair, vessel density or recovery of blood flow. Huang and colleagues (2015); Hsieh and colleagues (2017).

Original explanatory schematics. Cell shapes, fibre positions and arrangements are conceptual. The adjoining observations identify the cell and tissue measurements; the following sections develop their biological context.

Cell movement and attachment

A moving fibroblast repeatedly forms and releases attachments to the surrounding matrix, the material supporting the cells. These sites connect with actin fibres inside the cell, allowing changes in shape to produce movement. FAK, or focal adhesion kinase, is an enzyme that adds phosphate groups and participates in signaling at these attachments; paxillin helps organize proteins there. Phosphorylation—the addition of phosphate groups—can change how those proteins participate in signaling.

Chang and colleagues (2011) examined rat Achilles-tendon explants and isolated tendon fibroblasts. BPC-157 increased tissue outgrowth, migration, spreading and survival during hydrogen-peroxide stress. The investigators also observed more F-actin formation and increased FAK and paxillin phosphorylation, while total amounts of those proteins stayed similar. Their proliferation assays showed no direct stimulation. Taken together, the findings connect the outgrowth response with cell movement and survival and identify accompanying changes in the attachment machinery.

How the tendon-cell experiments measured movement

The transwell assay counted cells migrating through a filter, while spreading measurements examined changes in cell shape on a culture surface. Actin staining showed structural fibres, and protein assays distinguished phosphorylated FAK and paxillin from their total amounts. The study measured several related aspects of movement and attachment; it did not establish a directly bound BPC-157 target or test whether blocking FAK eliminated the response. Chang and colleagues (2011), Results and Figures 3–6.

Responsiveness to growth hormone

Once cells reach an injury, their response to surrounding signals can influence what they do. Growth hormone affects growth and protein production, prompting Chang and colleagues (2014) to examine its receptor in rat tendon fibroblasts. After one to three days of BPC-157 exposure, the cells contained more growth-hormone receptor RNA and protein. The investigators then supplied growth hormone separately and observed stronger JAK2 signaling, higher metabolic-activity readings and increased expression of PCNA, a protein associated with DNA replication.

The sequence of interventions explains the finding: BPC-157 exposure altered the cells' signaling machinery before the hormone arrived. JAK2 helps relay the receptor's signal inside the cell, so its response provides a functional companion to the receptor measurements. The experiment supports greater responsiveness to added hormone under those culture conditions. It measured neither circulating growth-hormone levels nor hormone release from the body.

Reading the growth-hormone assays together

MTT reports metabolic activity in a cell sample, which can change with cell number or with the activity of existing cells. PCNA expression supplies a proliferation-related measurement, and JAK2 phosphorylation follows signaling after hormone addition. Together, these assays explain the authors’ interpretation of the response. They provide indirect measures of proliferation, and the study did not remove the growth-hormone receptor to determine how much of the response depended on its increased abundance. Chang and colleagues (2014), Results 2.1–2.3.

Blood-vessel formation

Endothelial cells line blood vessels. They respond to vascular growth signals through receptors including VEGFR2, which receives VEGF-A. Changes in the receptor's abundance and movement within a cell can influence signaling even when the amount of incoming growth signal stays similar. Receptor internalization takes the receptor from the surface into an internal compartment, changing where its signal can be relayed. Downstream, Akt carries intracellular signals, and eNOS produces nitric oxide, a molecule involved in vascular signaling.

Hsieh and colleagues (2017) reported increased VEGFR2 expression and internalization, together with Akt–eNOS signaling changes, in cultured human endothelial cells. VEGF-A did not increase. Dynasore, which interferes with endocytosis, reduced the signaling and tube-formation responses, giving the proposed trafficking mechanism experimental support. Because dynasore affects uptake processes broadly, that comparison leaves the contribution of individual components incompletely resolved. In the rat hindlimb experiments, restricted circulation was followed by greater vessel density and improved blood-flow recovery with BPC-157. These tissue measurements extend the findings from cellular arrangement to vascular structure and perfusion.

Huang and colleagues (2015) also observed endothelial-cell migration and tube formation, alongside cell-cycle changes consistent with increased proliferation. In their alkali-burn rat model, wounds closed faster and showed better tissue organization. Their experiments reported increased VEGF-A and implicated ERK signaling through inhibitor comparisons. The difference from Hsieh's VEGF-A result remains part of the record, with each result attached to its own experimental conditions. Huang's endothelial proliferation findings likewise concern a different cell type from Chang's tendon fibroblasts.

A tube-formation assay follows cells arranging into connected structures on a culture surface. Vessel counts in tissue and measurements of blood flow examine additional functions. The teaching figure preserves these distinct outcomes so that an increase in cell assembly has a clear relationship to the animal vascular findings.

Protein turnover and the 2026 study

Cells regulate protein abundance through both production and breakdown. Zhang and colleagues (2026) studied this balance in human umbilical-vein endothelial cells. They reported BPC-157 binding to FBXO22, part of the machinery that tags selected proteins with ubiquitin for disposal. BACH1, a regulator of gene expression, increased at the protein level while its RNA remained similar. Protein-turnover experiments supported slower BACH1 breakdown, and reducing BACH1 reversed the observed metabolic-viability and tube-formation responses. This combination links a reported interaction with protein persistence and a measured cellular response.

The controls behind the FBXO22–BACH1 proposal

The authors used a scrambled-peptide comparison, binding assays, protein-turnover measurements and reductions of proposed pathway components. Their CCK-8 assay assessed metabolic viability. They also reported that endothelial cells exposed to severe cobalt-chloride injury failed to form tubes despite BPC-157 treatment, showing that the response depended on the cellular conditions. The exact binding-affinity value is omitted here because concentration descriptions and units differ across the paper’s methods and captions. Independent confirmation and the pathway’s contribution to recovery in tissue remain to be established. Zhang and colleagues (2026), Figures 3–6 and Discussion.

Pharmacokinetics

The culture experiments expose cells to a specified preparation in their immediate surroundings. In an animal, absorption and distribution determine which tissues encounter the peptide, while metabolism and elimination change the amount present over time. Pharmacokinetics describes that exposure. Pharmacodynamics follows the resulting biological response, whose timing can extend beyond the original signal.

Absorption and blood exposure

He and colleagues (2022) measured intact BPC-157 after intravenous and intramuscular administration in Sprague-Dawley rats and beagle dogs. Intravenous administration provided the reference for estimating intramuscular bioavailability from exposure over time, with the administered amounts accounted for. The reported fraction reaching circulation intact was approximately 14–19% in rats and 45–51% in dogs under the tested conditions.

The intravenous elimination half-life was 15.2 minutes in the rat analysis and a mean of 5.27 minutes in dogs. Half-life describes the time for concentration to fall by half during elimination. The rat value came from a profile assembled from mean concentrations: six different rats were sampled at each time point, with 66 allocated to the intravenous arm. The six dogs underwent repeated sampling. The table records these designs and preserves the reported dog standard deviation of 2.25 minutes; the rat table supplies no numerical standard deviation.

Breakdown and radioactive tracers

The study separately followed peptide-derived material using tritium labels on two proline residues. After breakdown, the label could remain in smaller fragments, proline or further metabolic products. Chemical analyses identified labelled proline and peptide fragments, while total radioactivity was detected in rat tissues and recovered through excretion, including urine and bile. Interpreting a tissue signal therefore requires knowing which labelled forms contributed to it.

An intact-peptide assay identifies the original BPC-157 molecule. A total-radioactivity assay collects signals from the labelled forms present in the sample. The two can follow different time courses as the molecule is metabolized. The schematic below shows why detection of peptide-derived material can continue after the original chain has broken apart.

Following the peptide and its labelled breakdown products

He and colleagues measured intact BPC-157 and conducted separate radioactive-tracer experiments. As the labelled chain breaks down, its fragments can contribute to the tracer signal.

Entry into circulation: Intravenous administration supplied the direct-to-blood reference. Intramuscular administration required absorption from the muscle before the peptide reached circulation.

Intact-peptide assay

Liquid chromatography–tandem mass spectrometry (LC-MS/MS) identifies the original molecule. Its plasma concentration changes as the peptide is distributed and broken down.

Total-radioactivity assay

The measured signal combines labelled forms present in the sample, including intact peptide, fragments and further metabolic products.

Tissues and excretion: Labelled material was detected in sampled rat tissues and recovered in urine and bile. Identifying the amount of intact peptide in a tissue would require an assay that distinguishes it from the labelled products.

Original explanatory schematic of the tracer experiment. Two prolines carried tritium labels. Selected breakdown products are shown; fragment sizes and label positions are illustrative. Source: He and colleagues (2022), Results 2.3 and Methods 4.1–4.6.

Reported intravenous elimination half-life of intact BPC-157
Model	Half-life	Sampling and uncertainty
Sprague-Dawley rats	15.2 min Estimate from mean plasma concentrations	6 rats at each time point Different animals sampled across time; numerical SD unavailable
Beagle dogs	5.27 min Reported mean; SD 2.25 min	6 dogs sampled repeatedly The same animals followed over time

The rat intravenous arm allocated 66 animals and calculated its parameter from mean concentrations. The dog parameter summarizes six repeatedly sampled animals. SD means standard deviation. Species, exposure conditions and sampling designs differed between the experiments. Source: He and colleagues (2022), Tables 1 and 4 and Methods 4.3–4.4.

He and colleagues measured intact BPC-157 in blood after injection into a vein in rats. The estimated elimination half-life was 15.2 minutes, meaning that the concentration fell by half over that interval during elimination. The estimate came from mean concentrations in six different rats at each time point, with 66 rats allocated to the intravenous arm. The rat table gives no numerical standard deviation for this estimate.

He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717.

Blood half-life and duration of response

A cell's response can involve changes in gene activity, protein abundance and behavior, followed by further stages of tissue remodeling. These processes can have a different time course from blood clearance. Establishing their duration for BPC-157 would require exposure and response measurements on a matched timeline; combining a blood half-life with a healing endpoint from another experiment cannot resolve it.

Route also affects the exposure being measured. Gastric-fluid stability describes survival in a digestive environment, while oral bioavailability requires absorption into circulation. The reviewed animal pharmacokinetic study established intravenous and intramuscular measurements. Human, oral and subcutaneous exposure remain uncharacterized in that report, leaving those routes without a verified concentration-time profile or half-life here.

Research findings

A direct comparison after tendon repair

Biçer and colleagues (2026) cut and surgically repaired Achilles tendons in 32 male rats, then compared four treatments given into the abdominal cavity: BPC-157, a preparation labelled TB-500, both together, and their carrying solution without either peptide. At day 30, they pulled four repaired tendons from each group until they broke and measured the maximum force sustained. Only the TB-500 group showed a statistically supported increase over the carrying-solution control on that strength measurement. Tendons from rats given BPC-157 also withstood more force than control tendons, but the difference was too uncertain to establish an effect (adjusted P = 0.389). The study did not establish that combining the two preparations made the repaired tendons withstand more pulling force than either preparation alone. Four tendons per group provide a small sample for this strength estimate. The surgically repaired injury and day-30 assessment also differ from the earlier experiment in which tendons were cut and left unrepaired.

Muscle and ligament repair

The Achilles-tendon findings introduced above form part of a wider set of acute injury experiments. Staresinic and colleagues (2006) followed rats for 72 days after complete quadriceps-muscle transection. They reported better mechanical performance and walking-related function, accompanied by microscopic evidence of regeneration. Following both function and tissue appearance helps assess whether the repair tissue contributes to the animal's movement.

Cerovecki and colleagues (2010) examined medial collateral ligament healing for 90 days after surgical transection. BPC-157 groups showed improvements in functional, mechanical and tissue-structure measurements. These longer observations extend the repair findings beyond the early postoperative period in the tendon study. Across the three tissues, the evidence concerns recovery from defined surgical injuries, with performance assessed alongside structural change.

Digestive injury and ulcerative colitis

Veljaca and colleagues (1995) studied chemically induced colon injury in rats using the name BPC-15. Systemic treatment preceded the injury and reduced both the damaged area and myeloperoxidase activity, a measurement associated with inflammatory-cell infiltration. Direct intracolonic treatment at the tested condition did not significantly improve those outcomes. The intervention timing makes this a protection experiment, and the route comparison is an important part of its result.

The FDA briefing document (2026) describes a 2005 conference abstract about ulcerative colitis. It reported 53 people randomly assigned to a rectal BPC-157 preparation or placebo, with 46 completing the two-week study. Five withdrew because of adverse events, described mainly as progression of colitis, and two were lost to follow-up. Both groups improved on a disease-activity score, and the confidence interval for the between-group difference included zero. The available account leaves a comparative treatment benefit unresolved. These historical details are attributed to FDA's summary because the complete original trial report was not obtained.

Knee pain and bladder symptoms in people

Lee and Padgett (2021) reviewed 17 knee-treatment records and reached 16 patients by telephone. Eleven of 12 patients given BPC-157 alone reported improvement, as did three of four given BPC-157 with thymosin beta-4. Most had been treated 6–12 months before the survey. The study captured patient-reported pain relief across several causes of knee pain, with no untreated or placebo group, standardized functional assessment or follow-up imaging. Those design choices limit attribution of the improvement and leave structural repair unmeasured.

Lee, Walker and Ayadi (2024) reviewed 12 women treated for persistent interstitial-cystitis symptoms after unsuccessful prior therapy. Following a procedure delivering BPC-157 into the bladder wall, ten reported complete symptom resolution and two reported 80% improvement. There was no comparison group. Repeat cystoscopy occurred at six weeks, but the paper described questionnaire timing inconsistently, making the symptom-response timeline difficult to reconstruct. The reported improvement is substantial within this small group; the relative contribution of the peptide, procedure and other influences requires a controlled comparison.

Safety and tolerability

Human safety observations remain brief and small. Lee and Burgess (2025) followed two adults, both previously exposed to intravenous BPC-157, through 24 hours after a second infusion. They reported no adverse symptoms or clinically significant adverse changes in the collected measurements. FDA's 2026 briefing also describes an older rectal-preparation study with 32 randomized healthy participants, 24 receiving active treatment, and no significant attributable adverse events. Headache and flatulence were the most frequently reported events in the older healthy-volunteer accounts, with no obvious difference from placebo. Sample size, prior exposure and short observation constrain what these reports can reveal about uncommon or delayed harms.

The animal toxicology assessment requires attention to laboratory measurements as well as the authors' overall conclusion. Xu and colleagues (2020) described BPC-157 as broadly well tolerated in their preclinical tests. FDA's July 2026 presentation identified possible clotting and liver concerns after 28 days of repeated intramuscular administration in rats and dogs. These findings warrant further investigation of the specific changes; they supply no incidence estimate for people.

BPC-157 has no FDA-approved medicinal product. The agency's current compounding safety page describes risks involving immune reactions, peptide-related impurities and incomplete characterization of the active ingredient. BPC-157 appears there among substances whose nominations were withdrawn. The briefing document additionally summarizes reports of injection-site reactions, shortness of breath and pigmentation changes involving BPC-containing products. Incomplete reports and additional ingredients complicate attribution. Preparation, route and exposure therefore remain consequential parts of the safety assessment.

What the research means

The strongest positive findings in this review come from animal injury studies that measured both tissue structure and performance. Tendon strength and walking, muscle mechanics and function, and ligament repair over longer follow-up provide complementary evidence within their respective models. The cellular work offers plausible contributions to that recovery: movement can affect which repair cells reach an injury, receptor abundance can alter their response to a signal, and vascular behavior can influence the surrounding supply of oxygen and nutrients.

These processes have been tested through different experiments, with different cells and endpoints. Linking them into a complete account of BPC-157-mediated recovery would require showing how the reported interactions affect injury outcomes and how that response depends on exposure. The 2026 protein-turnover study adds a specific intracellular proposal to investigate, while the animal pharmacokinetic measurements define one part of the exposure problem.

The published knee and bladder reports give human research concrete outcomes to examine: pain, urinary symptoms, function, structural recovery and duration of response. A controlled study with consistent follow-up could determine whether comparable patients improve more with BPC-157 than with placebo or usual care and could measure adverse effects at the same time. The current literature offers reasons to pursue those comparisons, while leaving the size of a human treatment benefit and its longer-term safety unresolved.

FAQs

Has BPC-157 been tested in people?

Yes. Lee and Padgett (2021) reported knee-pain outcomes, Lee, Walker and Ayadi (2024) reported interstitial-cystitis symptoms, and Lee and Burgess (2025) examined brief intravenous tolerability. The FDA briefing (2026) summarizes older rectal-preparation studies. The human-study section explains the patient groups and symptom measurements, while the digestive section develops the available placebo comparison.

Does BPC-157 heal tendons?

Staresinic and colleagues (2003) reported better-organized tissue, stronger tendons and improved walking in rats after complete Achilles-tendon transection. Human tendon recovery remains unresolved. Lee and Padgett (2021) measured reported pain relief across several causes of knee pain; their report included no follow-up imaging or tendon-strength assessment.

Is BPC-157 FDA-approved?

BPC-157 has no FDA-approved medicinal product. The FDA briefing (2026) evaluates the free base and acetate form and explains concerns about characterization, effectiveness and safety. Its discussion of the compounding bulk-substance list is an agency assessment presented to the advisory committee.

Are there different forms of BPC-157?

The free base and acetate salt share the BPC-157 peptide sequence. The molecular fields on this page identify the free base. The FDA identity table (2026) records variable acetate composition and supplies no single assigned molecular weight for that salt. Individual research papers sometimes leave the exact form unspecified.

Are oral and injected BPC-157 interchangeable?

Route determines how the peptide encounters digestive processing, absorption and distribution. He and colleagues (2022) measured intravenous and intramuscular exposure in animals. Gastric-fluid stability alone cannot establish oral absorption, and the reviewed evidence supplies no comparison showing equivalent exposure or clinical effects between oral and injected preparations in people.

What is BPC-157's half-life?

He and colleagues (2022) reported an intravenous elimination half-life of 15.2 minutes from the rat mean-concentration profile, using six rats per time point, and a mean of 5.27 minutes in six repeatedly sampled dogs. The dog standard deviation was 2.25 minutes. Human half-life and the duration of subsequent repair responses remain unmeasured in that study.

Does BPC-157 increase growth hormone?

Chang and colleagues (2014) measured growth-hormone receptor RNA and protein in rat fibroblasts. BPC-157 exposure increased receptor expression, and the cells responded more strongly after the investigators added growth hormone separately. Hormone production and circulating levels in people were outside the experiment.

What side effects have been reported?

The FDA briefing (2026) records headache and flatulence in older rectal-preparation studies, with no obvious difference from placebo. It also summarizes injection-site reactions, shortness of breath and pigmentation changes involving BPC-containing products. Missing details and additional ingredients complicate attribution. Lee and Burgess (2025) recorded no adverse symptoms in two adults during brief infusion monitoring. The available reports cannot provide reliable rates of uncommon or delayed reactions.

Does BPC-157 increase cancer risk?

The reviewed studies have not measured human cancer risk from BPC-157. Endothelial-cell and animal vascular experiments examine tube assembly, vessel density or perfusion, which cannot determine that risk. The FDA briefing (2026) identifies a lack of studies assessing carcinogenic potential. The safety implications of longer exposure remain unresolved.

Is BPC-157 the same as TB-500, KLOW or GLOW?

BPC-157 is the 15-residue peptide identified on this page. TB-500 names materials related to thymosin beta-4, while KLOW and GLOW name mixtures that may include BPC-157. Lee and Padgett (2021) described BPC-157 alone or combined with thymosin beta-4. Evidence about a named mixture requires identifying its exact components and studying the complete formulation. The BPC-157 and TB-500 comparison explains those identities.

Materials related to thymosin beta-4 appear alongside BPC-157 in some recovery discussions and in the small knee report. The BPC-157 and TB-500 comparison explains the identities and preparations behind those names. Thymosin beta-4 has its own parent-peptide literature, while the KLOW profile identifies a named mixture and examines the available evidence for its components and complete formulation.

References

Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155-61. DOI: 10.1002/jor.21107. PMID: 20225319.
A 90-day rat medial-collateral-ligament transection study with functional, mechanical and tissue-structure measurements.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-80. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672.
Rat tendon explants and fibroblasts showed greater outgrowth, migration, spreading and stress survival, accompanied by actin and attachment-signaling changes. The proliferation assays were unchanged.
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. DOI: 10.3390/molecules191119066. PMID: 25415472.
Rat tendon fibroblasts expressed more growth-hormone receptor RNA and protein, followed by stronger signaling and metabolic-activity responses when growth hormone was added separately.
He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717.
Intact-peptide measurements established animal intravenous and intramuscular exposure. Separate tritium experiments followed peptide-derived material through metabolism, tissue distribution and excretion.
Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. DOI: 10.1007/s00109-016-1488-y. PMID: 27847966.
Human endothelial-cell experiments examined VEGFR2 expression, internalization and signaling; rat hindlimb studies measured vessel density and recovery of blood flow.
Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy. 2015;9:2485-99. DOI: 10.2147/DDDT.S82030. PMID: 25995620.
The alkali-burn rat model supplied wound-closure and tissue-organization findings. Endothelial assays examined migration, cell-cycle distribution, tube formation and ERK-pathway involvement.
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435.
A knee-treatment chart review reached 16 patients by telephone and recorded reported pain improvement after BPC-157 alone or with thymosin beta-4.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17. PMID: 39325560.
Twelve women with persistent interstitial-cystitis symptoms reported substantial improvement after a local bladder procedure. The report provides a small clinical observation for controlled follow-up.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24. PMID: 40131143.
Two previously exposed adults underwent brief infusion monitoring, with no reported adverse symptoms or clinically significant adverse changes in the collected measurements.
Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-83. DOI: 10.1016/S0736-0266(03)00110-4. PMID: 14554208.
The rat Achilles-tendon transection experiment measured repair tissue, tendon mechanics and walking over 14 days, reporting improvement across those outcomes.
Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. 2006;24(5):1109-17. DOI: 10.1002/jor.20089. PMID: 16609979.
A 72-day rat quadriceps-transection experiment examined mechanical performance, walking-related function and microscopic regeneration.
Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. Journal of Pharmacology and Experimental Therapeutics. 1995;272(1):417-22. PMID: 7815358.
Systemic pretreatment reduced chemically induced rat colon damage and myeloperoxidase activity. Direct intracolonic treatment did not significantly improve those outcomes at the tested condition.
Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665. DOI: 10.1016/j.yrtph.2020.104665. PMID: 32334036.
This preclinical toxicology report supplies animal tolerability findings evaluated alongside FDA's later analysis of possible clotting and liver signals.
Zhang J, Liu M, Ou H, Wang Z, He L, Xiao Y, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling. 2026;24:149. DOI: 10.1186/s12964-026-02694-6.
Endothelial-cell binding, protein-turnover and component-reduction experiments support the authors' FBXO22–BACH1 proposal for the measured culture responses.
U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23–24, 2026. BPC-157-related bulk drug substances section. 2026.
FDA's assessment supplies chemical-form identity, historical human-study summaries, clinical-safety context and the agency's evaluation of the available evidence.
U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting: July 23, 2026 presentations. BPC-157-related bulk drug substances assessment. 2026.
FDA identifies laboratory signals potentially involving clotting and the liver after repeated intramuscular exposure in animals and summarizes clinical-safety observations.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 13 October 2026.
The current agency entry describes immune-reaction, impurity and active-ingredient-characterization concerns for BPC-157 among withdrawn nominations.
National Center for Biotechnology Information. PubChem Compound Summary: BPC-157, CID 9941957. Accessed 13 October 2026.
Compound identity record accompanying the free-base sequence map and molecular fields.
Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822–837. doi:10.52312/jdrs.2026.2951. PMID:42542926.
After surgical tendon repair in rats, researchers compared BPC-157, a product labelled TB-500, both peptides and injection liquid without either peptide. The study did not establish an added strength benefit from combining the peptides.

Clinical trial records

Four ClinicalTrials.gov records had no posted results when their official records were checked on 13 October 2026. The entries contain sponsor-entered plans and status reports. Their descriptions identify the clinical outcomes being proposed and several details that need clarification.

ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair. NCT07437547. The description concerns hamstring recovery alongside rehabilitation. The structured arm mappings list both interventions in both groups, leaving the treatment comparison unclear.
ClinicalTrials.gov. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. NCT07803250. The record gives different participant totals and conflicting descriptions of a saline comparison versus no treatment, so its study design needs clarification.
ClinicalTrials.gov. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. NCT07752381. The sponsor reports a completed single-group study of BPC-containing gummies. Registration followed the stated completion date, and results were unavailable in the record.
ClinicalTrials.gov. PCO-02 – Safety and Pharmacokinetics Trial. NCT02637284. This older record describes an oral safety and exposure study. Its last update was in 2015 and its current status was unknown when checked.

Glossary

Fibroblast: A cell that builds and maintains connective tissue, including the matrix around other cells.
Matrix: The supporting material surrounding cells, to which they attach and through which they move.
Focal adhesion: An attachment site connecting a cell's internal structural fibres with its surroundings.
Phosphorylation: Addition of a phosphate group to a molecule, often changing a protein's role in signaling.
Endothelial cell: A cell forming the inner lining of a blood vessel.
Internalization: Movement of a surface receptor or other material into a compartment within the cell.
Perfusion: Delivery of blood through a tissue.
Ubiquitin: A small protein attached to selected proteins, often marking them for disposal.
Bioavailability: The fraction of administered material reaching circulation intact, assessed relative to intravenous exposure.
Elimination half-life: The time for a measured concentration to fall by half during elimination.
Radioactive tracer: A detectable label used to follow material through the body, including products formed after the labelled molecule breaks down.
Standard deviation: A measure of the spread of observations around their mean.